Accessibility Menu
Imv logo

Imv(OTC) IMVIF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-100%
1 Year+1,500%
1 Month+1,500%
$0.00
+0.00%
+0.00Today
Imv last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-19
Imv stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-12
1 month+1,500%USD 0.002026-07-20
3 month+1,500%USD 0.002026-05-14
Year to date+1,500%USD 0.002025-12-30
1 year+1,500%USD 0.002025-08-06
3 year-99.95%USD 0.032023-08-18
5 year-100%USD 16.002021-08-20
Since inception-100%USD 8.662012-05-25

Imv Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$35.31M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.00

Volume

10

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.02

Estimated Earnings Date

Aug 21, 2026

IMVIF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Imv

IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both solid tumors and blood cancers.

Products and Services
  • DPX immune-modulating platform for cancer therapies
  • Flagship therapeutic maveropepimut-S in Phase II studies
  • Pipeline includes DPX-SurMAGE and DPX-COVID-19
Growth Outlook
  • Advancing maveropepimut-S through Phase II for multiple cancers
  • DPX-SurMAGE in Phase I for bladder cancer
  • Potential market expansion with infectious disease treatments
Financial Highlights
  • Cash and cash equivalents of $21.2 million as of Q4 2022
  • Operating expenses of $8.59 million reported in Q4 2022
  • Net income of -$8.64 million for Q4 2022
IMV Inc. is positioned in a promising sector with its innovative approach to cancer treatment. The company's focus on immuno-oncology and infectious diseases reflects a strategic alignment with current healthcare needs. The ongoing clinical trials for its lead product, maveropepimut-S, could significantly impact its market presence. Financially, while the company has reported losses, it maintains a solid cash position, which may support its ongoing research and development efforts. The potential for growth in both oncology and infectious disease markets presents an intriguing opportunity for investors interested in the biotechnology sector.
AI Generated • Aug 1, 2026

Industry

Biotechnology

Employees

97

CEO

Andrew Hall

Headquarters

Dartmouth, NS B3B 2C4, CA

IMVIF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-495.17%

Return on Capital

-173.43%

Return on Assets

-117.99%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

10

Avg. Volume

231.857

Financials (TTM)

Gross Profit

-$986.58K

Operating Income

-$39.41M

EBITDA

-$37.47M

Operating Cash Flow

-$32.86M

Capital Expenditure

-$1.06M

Free Cash Flow

-$33.92M

Cash & ST Invst.

$21.21M

Total Debt

$28.90M

Imv Performance Analysis

Imv annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
Imv sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-31N/A
Q22022-06-30N/A
Q32022-09-30N/A
Q42022-12-31N/A
Imv annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -4.93N/A
20222022-12-31USD -4.55-7.7%
Imv sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-318.5%
Q22022-06-307.7%
Q32022-09-3015.0%
Q42022-12-3111.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2022YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$322.49K

-54.1%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

63

N/A

Net Income

-$8.63M

+26.0%

EBITDA

-$8.27M

+25.2%

Quarterly Fundamentals

Name
Q4 2022YOY CHG

Total Cash

$21.21M

-45.0%

Total Debt

$28.90M

+47.2%

Accounts Receivable

$1.92M

+10.8%

Inventory

$0.00

N/A

Long Term Debt

$28.52M

+47.8%

Short Term Debt

$367.00K

+8.6%

Return on Assets

-1.18%

N/A

Return on Invested Capital

-1.80%

N/A

Free Cash Flow

-$6.51M

+18.4%

Operating Cash Flow

-$6.30M

+14.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EFTReFFECTOR Therapeutics, Inc.
$0.00+300.00%
CFRXQContraFect Corp.
$0.00+0.00%
OMMHOmnimmune Holdings, Inc.
$0.00-0.00%
ADYXAdynxx, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$41.20+0.06%
MSTRStrategy
$112.39+0.08%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.25-0.02%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$122.21+0.01%

Questions About IMVIF

What is the current price of Imv?

Imv is trading at $0.00 per share.

What is the 52-week range for Imv?

Over the past 52 weeks, Imv has traded between $0.00 and $0.02.

How much debt does Imv have?

As of the most recent reporting period, Imv reported total debt of $28.90M.

How much cash does Imv have on hand?

Imv reported $21.22M in cash and cash equivalents in its most recent financial results.

What is Imv’s dividend yield?

Imv does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.